Pfizer Inc (PFE)

Cash ratio

Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Cash and cash equivalents US$ in thousands 2,853,000 416,000 1,944,000 1,786,000 1,121,000
Short-term investments US$ in thousands 19,674,000 44,632,000 58,250,000 10,437,000 8,525,000
Total current liabilities US$ in thousands 47,794,000 42,138,000 42,671,000 25,920,000 37,304,000
Cash ratio 0.47 1.07 1.41 0.47 0.26

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($2,853,000K + $19,674,000K) ÷ $47,794,000K
= 0.47

The cash ratio of Pfizer Inc. has fluctuated over the past five years, indicating changes in the company's ability to cover its short-term obligations with its cash and cash equivalents. In 2021, Pfizer's cash ratio was at its highest point of 0.92, suggesting that the company had a strong liquidity position to meet its immediate financial commitments. However, in 2019, the cash ratio was at its lowest at 0.42, indicating a lower ability to cover short-term obligations with available cash.

The decreasing trend from 2021 to 2023 may signal a potential decrease in Pfizer's short-term liquidity position, which could raise concerns about its ability to address unexpected financial obligations. It is essential for investors and stakeholders to monitor this trend closely to assess Pfizer's overall financial health and risk exposure in the short term.


Peer comparison

Dec 31, 2023


See also:

Pfizer Inc Cash Ratio